Neurobiology of multiple sclerosis: from basic science to clinical translation
ECTRIMS Online Library. Lubetzki C. Oct 12, 2018; 232078; 326
Catherine Lubetzki
Catherine Lubetzki
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Discussion Forum (0)
Rate & Comment (0)

Abstract: 326

Type: Plenary Session

Abstract Category: N/A

Clinical disability in multiple sclerosis mostly relates to irreversible neuronal/axonal damage and loss. Such axonal pathology is likely to take place early in disease evolution, before becoming clinically eloquent years later, after reaching clinical threshold. Preventing neurodegeneration therefore represents a major challenge and unmet need in multiple sclerosis.
Recently the many and not exclusive causes of neuronal damage in multiple sclerosis have been deciphered. Neuronal alterations can be driven by the direct impact of the inflammatory cascade, and such changes can occur independently of demyelination. In contrast, other neuronal/axonal changes are the direct consequence of myelin disruption. Redistribution of voltage dependent sodium channels along the naked axons or axonal metabolic dysfunction due to disruption of oligodendrocyte coupling are examples of such “demyelination-dependent” axonal changes observed in a non inflammatory environment.
Prevention of neurodegeneration can be achieved through the development of neuroprotective drugs. Promoting remyelination is an alternative strategy for neuronal protection, as evidenced by both experimental studies and neuropathological analysis of multiple sclerosis demyelinated and remyelinated lesions on the one hand, by imaging methods in multiple sclerosis patients on the other hand.
I will review some recent studies generated using different and complementary experimental models, which have clarified the different cellular and molecular steps involved in the process of endogenous myelin repair. These results have paved the way for the identification of therapeutic targets, and to the development of screening tools to identify novel therapeutic candidates for myelin repair. After many years of experimental studies, clinical translation is ongoing in patients with multiple sclerosis. I will present and discuss the results of the few completed early phase clinical trials focusing on strategies aimed at promoting endogenous myelin repair and neuroprotection, as well as the rationale of studies that should take place in the near future.
Disclosure: CL participated to advisory boards for Roche, Biogen, Merck-Serono, Genzyme, Vertex. CL had a scientific collaboration with Vertex pharmaceutical company and has an ongoing scientific collaboration with Merck Serono

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings